Hormonal
SGLT-2 inhibitors, orlistat, phentermine/topiramate, metformin, tirzepatide, and Gelesis100 demonstrate varying degrees of efficacy in weight management, with SGLT-2 inhibitors showing mild but significant weight loss in non-diabetic obese patients.
Several other medications besides GLP-1 agonists can help with weight loss, including SGLT-2 inhibitors, orlistat, phentermine/topiramate, metformin, tirzepatide, and Gelesis100. Their effectiveness varies, with some showing significant weight loss and others showing mild but significant benefits. These options provide additional choices for patients who may not be candidates for or respond poorly to GLP-1 agonists.
Other options including sodium glucose co-transporter (SGLT) Inhibitors, orlistat, phentermine/topiramate, metformin, tirzepatide, Gelesis100 also demonstrated efficacy to various degrees... SGLT-2 inhibitors reduced weight in obese nondiabetic patients... Orlistat... showed efficacy on reducing visceral fat... Phentermine/topiramate also showed significant benefit... Metformin has been found to be effective... tirzepatide... led to significant and lasting reductions... Gelesis100, demonstrated greater weight loss over placebo
Why this rating
Supported by multiple RCTs and meta-analyses included in the review.
Source
Pharmacotherapeutics efficacy in obesity treatment: A systematic review
Tarboush BA et al. · International Journal of Advanced Community Medicine · 2023
DOI 10.33545/comed.2023.v6.i1a.256
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →